ArticleWorld journal of oncology2025
A Tertiary Lymphoid Structure-Related Gene Signature Predicts Prognosis and Treatment Response in Hepatocellular Carcinoma.
Article in World journal of oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Regulatory Role of Ribosome Biogenesis-Related Genes in Hepatocellular Carcinoma Prognosis and Construction of a Risk Prediction Model.Digestive diseases and sciences · 2026Article
- Beyond TLS Presence: A Functional Framework Integrating Maturity, Location, and Immune Context.Cancers · 2026Review
- Non-immune regulation of tertiary lymphoid structures in cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) carries a poor prognosis with limited treatment options. Tertiary lymphoid structures (TLS) impact tumor immunity, but their role in HCC requires clarification. This study aimed to develop and validate a TLS-related gene signature for predicting survival and therapeutic response in HCC, and to explore its mechanisms. Methods: We analyzed transcriptomic data from public databases (The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO)) using LASSO-Cox regression to identify a six-gene TLS signature (CCL20, CD200, PLAC8, DNASE1L3, C7, and SKAP1). We validated this TLS score across multiple independent HCC cohorts, including patients receiving transarterial chemoembolization (TACE), programmed cell death protein-1 (PD-1)/ligand 1 (PD-L1) inhibitors, or lenvatinib. Through single-cell RNA sequencing (scRNA-seq), we characterized immune microenvironment differences between score groups. Results: The TLS score effectively stratified patients' survival outcomes across all validation cohorts. Low TLS scores significantly correlated with improved overall survival, enhanced therapeutic response (especially to immune checkpoint inhibitors (ICIs)), and lower immune evasion potential. Mechanistically, scRNA-seq revealed distinct immune microenvironments: low-score tumors were enriched in cytotoxic and exhausted CD8 Conclusion: Our findings suggest a potential TLS-based biomarker for HCC prognosis and therapeutic response. This work offers preliminary insights into tumor immune microenvironment (TIME) heterogeneity, which may be modulated by the Treg/Tex balance, and proposes a possible tool for improving patient stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.